EN DE
Check 40,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Tempus AI, Inc. Class A (TEM) stock: price, quality, comparison

Price, quality, revenue and earnings and the peer comparison for Tempus AI, Inc. Class A, from audited financials.

Price: $76.05. Our models give no reliable value for this company right now, so we show no fair value.
  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

TA Tempus AI, Inc. Class A logo Thin data Jul 21, 2026

Tempus AI, Inc. Class A

TEM · US
Expensive Growth (revenue 5y +46.6 %/yr in USD)
Insiders sold $125.3M (6M)
Quality 37/100
Loss-making · -12.5% net margin (TTM)
High debt
Negative free cash flow
Trails peers (1/8)
Narrow moat 12/100
Thin data
No fair value

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Which stocks are undervalued right now? Check free Discover now →

Company profile

Tempus AI, Inc. operates as a healthcare technology company in the United States.

Show moreShow less

It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests.

The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses.

In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling.

Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application.

It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia.

The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 21
How much profit the company makes from its sales and capital
Quality Growth 80
Are margins and returns getting better?
Cashflow 9
Do the profits arrive as real cash?
Financial strength 52
Debt, balance sheet and risk of trouble
Investment 50
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 71
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 52
Distance to the 52-week high, does not count
New shares 28
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 9 officers or directors sold shares worth $125.3M and none bought.

  • SaleDavid R EpsteinDirector7× since Dec 1, 2025: 2,110 shares, avg. $59.63$125,825Nov 2, 202610b5-1 plan
  • SaleRyan FukushimaCEO, Data14× since Nov 18, 2025: 217,350 shares, avg. $55.97$12.2MNov 2, 2026
  • SaleEric P LefkofskyCEO and Chairman, Director, 10% owner17× since Nov 18, 2025: 2,881,592 shares, avg. $62.05$178.8MOct 27, 2026
  • SaleThomas Edward SchoenherrCEO, Diagnostics3× since May 19, 2026: 29,175 shares, avg. $64.22$1.9MSep 25, 2026
  • SaleRyan M BartolucciChief Accounting Officer5× since Nov 18, 2025: 22,089 shares, avg. $59.26$1.3MSep 17, 2026
  • SaleAndrew PolovinEVP, Chief Legal Officer6× since Nov 18, 2025: 85,287 shares, avg. $58.98$5.0MSep 17, 2026
  • SaleJennifer A DoudnaDirector5× since Nov 11, 2025: 7,201 shares, avg. $63.22$455,224Sep 1, 202610b5-1 plan
  • SaleNadja WestDirector2× since Aug 14, 2026: 6,000 shares, avg. $61.45$368,700Aug 28, 202610b5-1 plan
  • SaleJames William RogersChief Financial Officer7× since Nov 18, 2025: 119,945 shares, avg. $57.69$6.9MAug 19, 2026
  • SaleErik PhelpsEVP, Chief Admin. Officer3× since Nov 18, 2025: 14,299 shares, avg. $61.67$881,800Feb 19, 2026

Plus 1 more entries from the last 12 months.

Plus 13 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+83.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+58.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+46.6%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+65.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−102.9% (2020) → −18.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch TEM, get fair value alerts →

Compare Tempus AI, Inc. Class A Common Stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 118 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Profitability
Return on assets −10.8% · Bottom 25%
Net margin (12 months) −12.5% · Below median
Operating margin (12 months) −13.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 23.1% · Above median
Balance sheet
Debt / equity 2.52× · Highest 25%

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/B 28.23× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 9.19× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 48
PAST (return on equity)0 · sector 10
HEALTH (low debt)0 · sector 98
DIVIDEND (yield)0 · sector 41

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
HealthEquity, Inc HQY $103.63 $119.72 +16% vs TEM
Veeva Systems Inc VEEV $303.73 $341.69 +13% vs TEM
Doximity, Inc DOCS $32.51 $35.76 +10% vs TEM
Inventurus Knowledge Solutions Limited IKS ₹1,657 ₹1,823 +10% vs TEM
Waystar Holding WAY $28.35 $29.10 +3% vs TEM
Winning Health Technology Group 300253 ¥7.03 ¥3.44 −51% vs TEM
Hinge Health, Inc HNGE $115.76 $51.25 −56% vs TEM
Pro Medicus Limited PME A$205.13 A$85.12 −59% vs TEM
BrightSpring Health Services, Inc BTSG $67.15 $25.72 −62% vs TEM
Privia Health Group PRVA $24.42 $5.52 −77% vs TEM

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector

Frequently asked questions

What is the quality score of TEM?
Tempus AI, Inc. Class A has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Tempus AI, Inc. Class A (TEM)?
Tempus AI, Inc. Class A reported trailing-twelve-month revenue of about $1.5B (latest available figure, as of Jul 21, 2026).
How solid is the balance sheet of Tempus AI, Inc. Class A (TEM)?
Balance-sheet figures for Tempus AI, Inc. Class A (as of Jul 21, 2026): return on equity −37.6%, debt of 2.52 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
Which stocks are comparable to Tempus AI, Inc. Class A Common Stock?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
What is the share price of Tempus AI, Inc. Class A (TEM)?
The closing price on Nov 6, 2026 was $76.05. We carry closing prices from our data provider, not a live tick.

Key figures of Tempus AI, Inc. Class A

How large is the market capitalisation of Tempus AI, Inc. Class A (TEM)?
The market capitalisation of Tempus AI, Inc. Class A is $13.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tempus AI, Inc. Class A (TEM)?
The price-to-sales ratio of Tempus AI, Inc. Class A is 8.51 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Tempus AI, Inc. Class A (TEM)?
Earnings per share at Tempus AI, Inc. Class A are $−1.06. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Tempus AI, Inc. Class A (TEM)?
The net margin of Tempus AI, Inc. Class A is −12.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Tempus AI, Inc. Class A (TEM)?
The return on equity (ROE) of Tempus AI, Inc. Class A is −37.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tempus AI, Inc. Class A (TEM)?
On an EBIT basis the return on assets of Tempus AI, Inc. Class A is −41.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tempus AI, Inc. Class A (TEM)?
The operating margin of Tempus AI, Inc. Class A is −13.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tempus AI, Inc. Class A (TEM)?
Revenue at Tempus AI, Inc. Class A is growing +23.1% versus a year earlier (3y avg +58.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Tempus AI, Inc. Class A (TEM) generate?
The free cash flow of Tempus AI, Inc. Class A is −$239M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Tempus AI, Inc. Class A (TEM) carry?
The net debt of Tempus AI, Inc. Class A is $722M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Continue in the live analysis

Fair value and trend for 40,000+ stocks, watchlist, comparison and the diversification check.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.